HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German Rx-To-OTC Switch Committee To Consider Sildenafil Reclassification

Executive Summary

Rx-to-OTC switches of sildenafil and xylometazoline and ipratropium bromide combinations are on the cards for January's meeting of the German Expert Committee for Prescription.

You may also be interested in...

Petros Includes Nitrate Patients In OTC ED Drug Self-Selection Studies

Firms also notes in its announcement that FDA typically requires actual use trials for switch NDAs in addition to label comprehension studies, which it has conducted, and self-selection studies.

Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug

Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.

UK Approves Switch Of Higher Dose Calcium And Vitamin D Combination

The MHRA has approved the switch of Consilient Health's Calci-D, which will offer UK consumers the highest dose of vitamin D3 available in combination with calcium as an OTC medicine.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts